PE20120990A1 - Formulaciones de alisquireno e hidroclorotiazida - Google Patents
Formulaciones de alisquireno e hidroclorotiazidaInfo
- Publication number
- PE20120990A1 PE20120990A1 PE2012000368A PE2012000368A PE20120990A1 PE 20120990 A1 PE20120990 A1 PE 20120990A1 PE 2012000368 A PE2012000368 A PE 2012000368A PE 2012000368 A PE2012000368 A PE 2012000368A PE 20120990 A1 PE20120990 A1 PE 20120990A1
- Authority
- PE
- Peru
- Prior art keywords
- hydrochlorothiazide
- weight
- alisquirene
- formulations
- dosage form
- Prior art date
Links
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002003 hydrochlorothiazide Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 229940100445 wheat starch Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDA A UNA FORMA DE DOSIFICACION SOLIDA QUE COMPRENDE: a) DE 25% A 47% EN PESO DE ALISQUIRENO, b) 0,5% A 10% EN PESO DE HIDROCLOROTIAZIDA (HCTZ) Y c) 3% A 30% EN PESO DE UN RELLENO HIDROFILICO COMPRENDIDO DE UNA MEZCLA DE ALMIDON DE TRIGO Y LACTOSA. LA COMPOSICION TAMBIEN COMPRENDE UN RELLENO ADICIONAL, UN DESINTEGRANTE TAL COMO PVP RETICULADA, UN LUBRICANTE, UN DESLIZANTE, UN AGLUTINANTE. DICHA FORMA DE DOSIFICACION ORAL SE ENCUENTRA BAJO LA FORMA DE TABLETA O TABLETA RECUBIERTA POR UNA PELICULA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0612540.5A GB0612540D0 (en) | 2006-06-23 | 2006-06-23 | Galenical formulations of organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120990A1 true PE20120990A1 (es) | 2012-08-16 |
Family
ID=36803824
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000804A PE20080373A1 (es) | 2006-06-23 | 2007-06-22 | Formulaciones de alisquireno e hidroclorotiazida |
| PE2012000368A PE20120990A1 (es) | 2006-06-23 | 2007-06-22 | Formulaciones de alisquireno e hidroclorotiazida |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000804A PE20080373A1 (es) | 2006-06-23 | 2007-06-22 | Formulaciones de alisquireno e hidroclorotiazida |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8618172B2 (es) |
| EP (3) | EP2311439A1 (es) |
| JP (1) | JP5362556B2 (es) |
| KR (1) | KR101442272B1 (es) |
| CN (1) | CN101472566A (es) |
| AR (1) | AR061565A1 (es) |
| AU (1) | AU2007263261B2 (es) |
| BR (1) | BRPI0713338A2 (es) |
| CA (1) | CA2654872A1 (es) |
| CL (1) | CL2007001837A1 (es) |
| EC (1) | ECSP088986A (es) |
| ES (1) | ES2704979T3 (es) |
| GB (1) | GB0612540D0 (es) |
| GT (1) | GT200800297A (es) |
| IL (1) | IL195425A (es) |
| MA (1) | MA30527B1 (es) |
| MX (1) | MX2008016533A (es) |
| MY (1) | MY146779A (es) |
| NO (1) | NO20090262L (es) |
| NZ (1) | NZ572937A (es) |
| PE (2) | PE20080373A1 (es) |
| RU (1) | RU2491058C2 (es) |
| TN (1) | TNSN08528A1 (es) |
| TW (1) | TWI457137B (es) |
| WO (1) | WO2007147596A1 (es) |
| ZA (1) | ZA200809773B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091203A1 (es) * | 2007-09-28 | 2009-09-11 | Novartis Ag | Composiciones farmaceuticas que comprende alisquireno o una sal farmaceuticamente aceptable del mismo |
| EP2143425A1 (de) * | 2008-07-11 | 2010-01-13 | Ratiopharm GmbH | Direktverpresste Aliskiren-Tabletten |
| JP2010031006A (ja) * | 2008-07-17 | 2010-02-12 | Novartis Ag | 有機化合物の使用 |
| ES2365429B1 (es) | 2010-03-05 | 2012-09-06 | Universidad De Castilla De La Mancha | Solucion para dialisis peritoneal |
| CN102626391B (zh) * | 2012-04-19 | 2013-07-10 | 海南美兰史克制药有限公司 | 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂 |
| EP2968182B8 (en) * | 2013-03-15 | 2018-07-25 | SpecGx LLC | Abuse deterrent solid dosage form for immediate release with functional score |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| TW442301B (en) | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| US6010719A (en) * | 1997-09-16 | 2000-01-04 | Universiteit Gent | Freeze-dried disintegrating tablets |
| PE20001302A1 (es) | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida |
| US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| IS1935B (is) * | 2002-03-19 | 2004-06-16 | Actavis Group Hf. | Fósínópríl lyfjasamsetning |
| US20050182042A1 (en) * | 2002-05-17 | 2005-08-18 | Feldman David L. | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| BG65538B1 (bg) * | 2002-07-05 | 2008-11-28 | "Софарма" Ад | Лекарствена форма на силимарин и метод за нейнотополучаване |
| WO2005077418A1 (en) * | 2004-02-17 | 2005-08-25 | Novartis Ag | Combination of renin inhibitor and diuretics |
| PE20142101A1 (es) * | 2004-03-17 | 2014-12-27 | Novartis Ag | Composiciones farmaceuticas de aliskiren |
| ATE493973T1 (de) * | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| WO2006041763A1 (en) | 2004-10-04 | 2006-04-20 | Novartis Ag | Renin inhibitors for treating transplantation induced diseases |
| US8367105B2 (en) * | 2004-11-10 | 2013-02-05 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| AU2006241219A1 (en) * | 2005-04-27 | 2006-11-02 | Novartis Ag | Methods of treating atherosclerosis |
| US20080255084A1 (en) * | 2005-10-21 | 2008-10-16 | Randy Lee Webb | Combination of Organic Compounds |
-
2006
- 2006-06-23 GB GBGB0612540.5A patent/GB0612540D0/en not_active Ceased
-
2007
- 2007-06-21 EP EP10191022A patent/EP2311439A1/en not_active Withdrawn
- 2007-06-21 MY MYPI20084990A patent/MY146779A/en unknown
- 2007-06-21 BR BRPI0713338-3A patent/BRPI0713338A2/pt not_active IP Right Cessation
- 2007-06-21 JP JP2009515768A patent/JP5362556B2/ja not_active Expired - Fee Related
- 2007-06-21 CN CNA2007800225770A patent/CN101472566A/zh active Pending
- 2007-06-21 ES ES07785832T patent/ES2704979T3/es active Active
- 2007-06-21 WO PCT/EP2007/005476 patent/WO2007147596A1/en active Application Filing
- 2007-06-21 US US12/304,244 patent/US8618172B2/en active Active
- 2007-06-21 EP EP18177693.1A patent/EP3391878A1/en not_active Withdrawn
- 2007-06-21 MX MX2008016533A patent/MX2008016533A/es active IP Right Grant
- 2007-06-21 KR KR1020087031081A patent/KR101442272B1/ko not_active Expired - Fee Related
- 2007-06-21 NZ NZ572937A patent/NZ572937A/en not_active IP Right Cessation
- 2007-06-21 AU AU2007263261A patent/AU2007263261B2/en not_active Ceased
- 2007-06-21 EP EP07785832.2A patent/EP2034968B1/en active Active
- 2007-06-21 AR ARP070102734A patent/AR061565A1/es unknown
- 2007-06-21 CA CA002654872A patent/CA2654872A1/en not_active Abandoned
- 2007-06-21 RU RU2009101971/15A patent/RU2491058C2/ru not_active IP Right Cessation
- 2007-06-22 TW TW096122538A patent/TWI457137B/zh not_active IP Right Cessation
- 2007-06-22 PE PE2007000804A patent/PE20080373A1/es not_active Application Discontinuation
- 2007-06-22 CL CL200701837A patent/CL2007001837A1/es unknown
- 2007-06-22 PE PE2012000368A patent/PE20120990A1/es not_active Application Discontinuation
-
2008
- 2008-11-17 ZA ZA200809773A patent/ZA200809773B/xx unknown
- 2008-11-20 IL IL195425A patent/IL195425A/en not_active IP Right Cessation
- 2008-12-17 GT GT200800297A patent/GT200800297A/es unknown
- 2008-12-17 EC EC2008008986A patent/ECSP088986A/es unknown
- 2008-12-19 TN TNP2008000528A patent/TNSN08528A1/en unknown
- 2008-12-24 MA MA31502A patent/MA30527B1/fr unknown
-
2009
- 2009-01-16 NO NO20090262A patent/NO20090262L/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2005000795A (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
| ECSP088239A (es) | Composición de liberación de fármaco sostenida | |
| PE20120990A1 (es) | Formulaciones de alisquireno e hidroclorotiazida | |
| CO6150163A2 (es) | Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidina | |
| PE20110121A1 (es) | Composiciones farmaceuticas de aliskiren | |
| HN2008001530A (es) | Compuestos de amino pirimidina 2,6- sustituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2 | |
| MY177741A (en) | Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate. | |
| ECSP088240A (es) | Composición de trazodona para administración una vez por día | |
| CO6400186A2 (es) | Tabletas de acetato de ulipristal | |
| CY1124914T1 (el) | Στερεες φαρμακευτικες συνθεσεις που περιεχουν αναστολεα ιντεγκρασης | |
| EA200701065A1 (ru) | Инъецируемые составы, содержащие нанодисперсный оланзапин | |
| CY1113462T1 (el) | Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο | |
| CY1110097T1 (el) | Διπλοστοιβαδικο δισκιο για προληψη καρδιαγγειακων συμβαντων | |
| CO6150126A2 (es) | Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina | |
| MA29278B1 (fr) | Composition pharmaceutique comprenant un derive de l'indolylmaleimide | |
| UA109627C2 (uk) | Композиції тетрациклінових сполук для орального введення та ін'єкцій | |
| PE20090371A1 (es) | Formulacion de nevirapina de liberacion prolongada | |
| CO6321223A2 (es) | Formulacion farmaceutica solida que contiene ciclostazol | |
| UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| EA201170913A1 (ru) | Фармацевтические составы олмесартана | |
| PE20090066A1 (es) | Composiciones farmaceuticas en base a granulos de un derivado de azidocitidina y un copolimero de bloques y procedimiento de preparacion | |
| ATE530172T1 (de) | Pharmazeutische formulierungen mit clopidogrel | |
| ATE474558T1 (de) | Pharmazeutische formulierungen mit irbesartan | |
| ATE357220T1 (de) | Pharmazeutische zusammensetzung mit modifizierter freisetzung | |
| PE20091522A1 (es) | Composicion farmaceutica solida que contiene 3-(1.h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-quinazolin-4-il]-pirrol-2,5-diona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |